AR005658A1 - Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina. - Google Patents

Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina.

Info

Publication number
AR005658A1
AR005658A1 ARP970100204A ARP970100204A AR005658A1 AR 005658 A1 AR005658 A1 AR 005658A1 AR P970100204 A ARP970100204 A AR P970100204A AR P970100204 A ARP970100204 A AR P970100204A AR 005658 A1 AR005658 A1 AR 005658A1
Authority
AR
Argentina
Prior art keywords
nucleic acid
determining region
coding
isolated nucleic
monoclonal antibody
Prior art date
Application number
ARP970100204A
Other languages
English (en)
Original Assignee
Univ Vermont
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Vermont, Smithkline Beecham Corp filed Critical Univ Vermont
Publication of AR005658A1 publication Critical patent/AR005658A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Uso de un anticuerpo monoclonal anti-factor de coagulación para la preparación de un medicamento para inhibir trombosis en un animal, quecomprende una dosis eficaz de un anticuerpo monoclonal anti-factor de coagulación que tieneac tividad neutralizante autolimitante. Se describe ademásun anticuerpo monoclonal anti-factor de coagulación, un hibridoma, un fragmento fab neutralizante, una región determinante de complementariedad de la cadenapesada de inmunoglobulina, unamolécula de ácido nucleico, un anticuerpo alterado y humanizado y una composición farmacéutica.
ARP970100204A 1996-01-17 1997-01-17 Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina. AR005658A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1010896P 1996-01-17 1996-01-17
US2911996P 1996-10-24 1996-10-24

Publications (1)

Publication Number Publication Date
AR005658A1 true AR005658A1 (es) 1999-07-14

Family

ID=26680794

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP970100204A AR005658A1 (es) 1996-01-17 1997-01-17 Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina.

Country Status (26)

Country Link
US (5) US6005091A (es)
EP (2) EP1832297A1 (es)
JP (2) JP2000503210A (es)
KR (1) KR100553629B1 (es)
CN (1) CN1213312A (es)
AR (1) AR005658A1 (es)
AT (1) ATE330630T1 (es)
AU (1) AU706397B2 (es)
BR (1) BR9707049A (es)
CZ (1) CZ299452B6 (es)
DE (1) DE69736197T2 (es)
DK (1) DK1007089T3 (es)
ES (1) ES2267131T3 (es)
HK (1) HK1029513A1 (es)
HU (1) HU225903B1 (es)
ID (1) ID17156A (es)
IL (1) IL125380A0 (es)
MA (1) MA24512A1 (es)
MX (1) MX9805810A (es)
NO (1) NO983284L (es)
NZ (2) NZ501215A (es)
PL (1) PL187274B1 (es)
PT (1) PT1007089E (es)
SI (1) SI1007089T1 (es)
TR (1) TR199801390T2 (es)
WO (1) WO1997026010A1 (es)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20040038898A1 (en) * 1996-05-16 2004-02-26 The Trustees Of Columbia University Method for inhibiting thrombosis in a patient whose blood is subjected to extracorporeal circulation
US6610293B1 (en) 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
WO1999001476A1 (en) * 1997-07-03 1999-01-14 Smithkline Beecham Corporation CRYSTAL STRUCTURES OF ANTI-FACTOR IX Fab FRAGMENTS AND METHODS OF USE FOR PEPTIDOMIMETIC DESIGN
DE19802139C1 (de) * 1998-01-22 1999-09-23 Centeon Pharma Gmbh Monoklonaler Antikörper spezifisch für aktivierten Gerinnungsfaktor VII und seine Verwendung
WO1999058680A2 (en) * 1998-05-08 1999-11-18 Stichting Sanquin Bloedvoorziening Method for diagnosis and treatment of haemophilia a patients with an inhibitor
US7250494B2 (en) * 1998-06-15 2007-07-31 Biosynexus Incorporated Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
WO2000007626A1 (en) * 1998-08-07 2000-02-17 Smithkline Beecham Corporation Use of anti-coagulation factor antibodies as long-lasting protective agents
AU766551C (en) 1998-08-28 2005-02-17 Genentech Inc. Human anti-factor IX/IXa antibodies
AU766149B2 (en) * 1998-10-31 2003-10-09 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Variants of humanized anti-carcinoma monoclonal antibody CC49
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
JP4297207B2 (ja) * 1999-07-14 2009-07-15 ライフ・サイエンシーズ・リサーチ・パートナーズ・フェレニゲング・ゾンデル・ウィンストーメルク 止血障害処置のための治療組成物に使用するためのリガンド
US7829085B2 (en) 1999-07-14 2010-11-09 Life Sciences Research Partners Vzw Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII
US7067313B1 (en) 1999-07-14 2006-06-27 D. Collen Research Foundation Ligands for use in therapeutic compositions for the treatment of hemostasis disorders
AT411997B (de) 1999-09-14 2004-08-26 Baxter Ag Faktor ix/faktor ixa aktivierende antikörper und antikörper-derivate
US6316259B1 (en) * 2000-01-21 2001-11-13 Isis Pharmaceuticals, Inc. Antisense inhibition of glycogen synthase kinase 3 alpha expression
WO2001087339A1 (en) * 2000-05-15 2001-11-22 Smithkline Beecham Corporation Antithrombotic agents
EP2322648A1 (en) * 2000-09-26 2011-05-18 Duke University RNA aptamers and methods for identifying the same
DK1222929T3 (da) 2001-01-11 2010-09-06 Life Sciences Res Partners Vzw Fremgangsmåde og farmaceutisk sammensætning til forebyggelse og/eller behandling af systematisk betændelsesreaktionssyndrom
US20030091574A1 (en) * 2001-03-23 2003-05-15 Gevas Philip C. Combination treatment of pancreatic cancer
US20090191232A1 (en) * 2001-05-04 2009-07-30 Gevas Philip C Combination therapy for the treatment of tumors
EP1396539B1 (en) * 2001-06-12 2008-11-26 Juridical Foundation, The Chemo-Sero-Therapeutic Research Institute Human-type anti-blood coagulation factor viii antibody
CA2450898A1 (en) * 2001-07-09 2003-01-23 Aphton Corporation Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus
US20080219998A1 (en) * 2001-12-07 2008-09-11 Andras Gruber Anti-Thrombotic Agents
US20040052779A1 (en) * 2001-12-21 2004-03-18 Stinson Jeffrey R. Opsonic monoclonal and chimeric antibodies specific for lipoteichoic acid of Gram positive bacteria
US7569673B2 (en) 2002-06-28 2009-08-04 The United States Of America As Represented By The Department Of Health And Human Services Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors
US6928528B1 (en) 2002-10-07 2005-08-09 Advanced Micro Devices, Inc. Guaranteed data synchronization
US20060020119A1 (en) * 2004-03-29 2006-01-26 Stephen Grimes Monoclonal antibodies to gastrin hormone
CN1781023A (zh) * 2003-03-28 2006-05-31 埃弗顿有限公司 胃泌素激素免疫测定
JP4422430B2 (ja) 2003-05-14 2010-02-24 帝國製薬株式会社 エストロゲン及び／又はプロゲストゲン含有外用貼付剤
ES2412489T3 (es) 2003-08-14 2013-07-11 Thrombogenics N.V. Anticuerpos contra el factor VIII con glucosilación modificada en la región variable
US7589181B2 (en) 2003-08-29 2009-09-15 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Minimally immunogenic variants of SDR-grafted humanized antibody CC49 and their use
US7297336B2 (en) 2003-09-12 2007-11-20 Baxter International Inc. Factor IXa specific antibodies displaying factor VIIIa like activity
AU2003271174A1 (en) * 2003-10-10 2005-04-27 Chugai Seiyaku Kabushiki Kaisha Double specific antibodies substituting for functional protein
WO2005035754A1 (ja) * 2003-10-14 2005-04-21 Chugai Seiyaku Kabushiki Kaisha 機能蛋白質を代替する二重特異性抗体
JP2008513536A (ja) 2004-09-22 2008-05-01 レセプター バイオロジックス インコーポレイテッド プロガストリンに対するモノクローナル抗体
WO2006106905A1 (ja) 2005-03-31 2006-10-12 Chugai Seiyaku Kabushiki Kaisha 会合制御によるポリペプチド製造方法
US11046784B2 (en) 2006-03-31 2021-06-29 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
DK2009101T3 (en) 2006-03-31 2018-01-15 Chugai Pharmaceutical Co Ltd Antibody modification method for purification of a bispecific antibody
CA2666905A1 (en) * 2006-10-16 2008-06-05 Novelmed Therapeutics, Inc. Method of inhibiting coagulation with human anti-factor va antibodies and use thereof
EP2197914A1 (en) 2007-09-13 2010-06-23 Delenex Therapeutics AG HUMANIZED ANTIBODIES AGAINST THE ß-AMYLOYD PEPTIDE
EP2185592B1 (en) * 2007-09-13 2013-01-23 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
SI2202245T1 (sl) 2007-09-26 2016-10-28 Chugai Seiyaku Kabushiki Kaisha Postopek modificiranja izoelektrične točke protitelesa preko aminokislinske substitucije v CDR
WO2009049234A2 (en) * 2007-10-11 2009-04-16 Regents Of The University Of California Methods of treating coagulopathy
ES2702365T3 (es) * 2008-06-19 2019-02-28 Prothix Bv Uso de anticuerpos antifactor XI para la prevención o el tratamiento de la formación de trombos
CN105859889B (zh) 2010-11-17 2020-01-07 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
WO2014100740A1 (en) 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
WO2014160088A2 (en) * 2013-03-14 2014-10-02 Rhode Island Hospital, A Lifespan-Partner Treating hepatitis b virus infections
BR112016006197B1 (pt) 2013-09-27 2023-04-11 Chugai Seiyaku Kabushiki Kaisha Método para produzir um anticorpo biespecífico de polipeptídeos
DK3177642T3 (da) 2014-08-07 2022-02-21 Novartis Ag Angiopoietin-lignende 4-antistoffer og fremgangsmåder til anvendelse deraf
EP3194437B1 (en) 2014-08-07 2021-01-20 Novartis AG Angiopoietin-like 4 (angptl4) antibodies and methods of use
TWI700300B (zh) 2014-09-26 2020-08-01 日商中外製藥股份有限公司 中和具有第ｖｉｉｉ凝血因子（ｆｖｉｉｉ）機能替代活性的物質之抗體
TWI701435B (zh) 2014-09-26 2020-08-11 日商中外製藥股份有限公司 測定ｆｖｉｉｉ的反應性之方法
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
WO2016159213A1 (ja) 2015-04-01 2016-10-06 中外製薬株式会社 ポリペプチド異種多量体の製造方法
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
EP3398965A4 (en) 2015-12-28 2019-09-18 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PROMOTING THE EFFICACY OF PURIFYING A POLYPEPTIDE CONTAINING AN FC REGION
KR20180104036A (ko) 2016-01-22 2018-09-19 머크 샤프 앤드 돔 코포레이션 항-응고 인자 xi 항체
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
CN116425879A (zh) 2016-06-14 2023-07-14 默沙东有限责任公司 抗-凝血因子xi抗体
EP3509637A4 (en) 2016-09-06 2020-05-27 Chugai Seiyaku Kabushiki Kaisha METHODS OF USING A BISPECIFIC ANTIBODY THAT RECOGNIZES COAGULATION FACTOR IX AND / OR ACTIVATED COAGULATION FACTOR IX AND COAGULATION FACTOR X AND / OR ACTIVATED COAGULATION FACTOR X
CN110325211A (zh) * 2016-12-23 2019-10-11 诺华股份有限公司 采用抗因子XI/XIa抗体治疗的方法
CN110325550B (zh) 2016-12-23 2024-03-08 诺华股份有限公司 因子xi抗体和使用方法
AU2018283284B2 (en) 2017-06-15 2024-05-16 Cancer Advances Inc. Compositions and methods for inducing humoral and cellular immunities against tumors and cancer
GB201709970D0 (en) * 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
CA3071236A1 (en) 2017-09-29 2019-04-04 Chugai Seiyaku Kabushiki Kaisha Multispecific antigen-binding molecule having blood coagulation factor viii (fviii) cofactor function-substituting activity, and pharmaceutical formulation containing said molecule as active ingredient
LT3723858T (lt) 2018-12-21 2022-02-10 Kymab Limited Fixaxfx bispecifiniai antikūnai, turintys bendrą lenvąją grandinę

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3909799A1 (de) * 1989-03-24 1990-09-27 Behringwerke Ag Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
CA2049655C (en) * 1990-09-17 1996-11-12 Akio Odawara Pharmaceutical composition for inhibiting platelet aggregation
WO1993009804A1 (en) * 1991-11-18 1993-05-27 The Scripps Research Institute Serine protease derived-polypeptides and anti-peptide antibodies, systems and therapeutic methods for inhibiting coagulation
US5383928A (en) * 1992-06-10 1995-01-24 Emory University Stent sheath for local drug delivery
EP0658168B1 (en) * 1992-08-27 2000-11-15 Stichting Sanquin Bloedvoorziening Antibodies specific for a haemostatic protein, their use for isolating intact protein, haemostatic compositions devoid of proteolytic cleavage products of the protein
US5397581A (en) * 1993-02-05 1995-03-14 Lerman; Russell E. Means for continuous confectionery coating of edible centers
MA24512A1 (fr) * 1996-01-17 1998-12-31 Univ Vermont And State Agrienl Procede pour la preparation d'agents anticoagulants utiles dans le traitement de la thrombose
US20070190059A1 (en) * 1996-01-17 2007-08-16 Smithkline Beecham Corporation Antithrombotic agents

Also Published As

Publication number Publication date
CN1213312A (zh) 1999-04-07
PL187274B1 (pl) 2004-06-30
NZ331014A (en) 2000-01-28
PT1007089E (pt) 2006-11-30
HUP9900396A2 (hu) 1999-05-28
MX9805810A (es) 1998-11-30
US20020146411A1 (en) 2002-10-10
AU1830897A (en) 1997-08-11
SI1007089T1 (sl) 2006-12-31
EP1832297A1 (en) 2007-09-12
KR19990077329A (ko) 1999-10-25
KR100553629B1 (ko) 2006-10-04
EP1007089B1 (en) 2006-06-21
AU706397B2 (en) 1999-06-17
IL125380A0 (en) 1999-03-12
DE69736197D1 (de) 2006-08-03
JP2000503210A (ja) 2000-03-21
NO983284D0 (no) 1998-07-16
DK1007089T3 (da) 2006-10-09
JP2007325602A (ja) 2007-12-20
HUP9900396A3 (en) 2001-10-29
NO983284L (no) 1998-09-16
TR199801390T2 (xx) 1998-12-21
EP1007089A1 (en) 2000-06-14
NZ501215A (en) 2001-04-27
HU225903B1 (en) 2007-12-28
EP1007089A4 (en) 2003-04-16
CZ222598A3 (cs) 2000-01-12
CZ299452B6 (cs) 2008-07-30
US6005091A (en) 1999-12-21
ATE330630T1 (de) 2006-07-15
ID17156A (id) 1997-12-04
US20070003553A1 (en) 2007-01-04
HK1029513A1 (en) 2001-04-06
DE69736197T2 (de) 2007-06-21
US6391299B1 (en) 2002-05-21
US20070224198A1 (en) 2007-09-27
MA24512A1 (fr) 1998-12-31
PL327929A1 (en) 1999-01-04
ES2267131T3 (es) 2007-03-01
BR9707049A (pt) 2000-10-24
WO1997026010A1 (en) 1997-07-24

Similar Documents

Publication Publication Date Title
AR005658A1 (es) Una molecula de acido nucleico aislada que codifica la región determinante de complementariedad de inmunoglobulina.
CY1119353T1 (el) Θεραπευτικη χρηση αντισωματων anti-cs1
NO2006008I1 (no) Natalizumab, anti alfa-4 integrin humanized monoclonal antibody
ATE531812T1 (de) Humanisierung von nager-antikörpern
CO5160384A1 (es) Anticuerpo humanizado especifico para 4-1bb humano y composicion farmaceutica que comprende el mismo
DE69429095D1 (de) Humanisierte antikoerper
HRP20020693B1 (en) HUMANIZED ANTIBODIES THAT SEQUESTER AMYLOID Abeta PEPTIDE
BR9507594B8 (pt) Anticorpo monoclonal com scfv humanizado, molécula de ácido nucleico recombinante e proteína recombinante.
MX9504802A (es) Anticuerpos anti-egfr y fvs de cadena simple anti-egfr.
DE69940364D1 (de) Fab Fragmentbibliotheken und Verfahren für deren Verwendung
UA111707C2 (uk) Застосування виділеного анти-tnf-альфа антитіла людини
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
FI943635A (fi) Ihmisen interleukiini-5:n vastaisten humanisoitujen monoklonaalisten vasta-aineiden suunnittelu, kloonaus ja ekspressio
RS52889B (sr) Terapijsko humano anti-il-1r1 monoklonsko antitelo
DK0918797T3 (da) Humaniseret immunglobulin reaktivt med alpha4beta7 integrin
BR9607171A (pt) Anticorpos monoclonais anti-cd6 e usos dos mesmos
ATE509955T1 (de) Humanisierte kollagen-antikörper und damit verbundene verfahren
ES2173130T3 (es) Metodo de fijacion de material al peptido beta-amiloide.
IT1271461B (it) Anticorpo monoclonale bispecifico anti-cd3/anti-egfr,processo per la produzione e suo uso.
EE04752B1 (et) Monoklonaalne antikeha, seda tootev hübridoom ja antikeha kasutamine
BR0207151A (pt) Moléculas de aglutinação terapêuticas
EA200400930A1 (ru) Блокирующее моноклональное антитело к vla-1 или его применение для лечения воспалительных заболеваний
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
ATE296316T1 (de) Gegen menschliches mcm3-protein gerichtete monoklonale antikörper, verfahren zu deren herstellung und deren verwendung
ES2062762T3 (es) Metodo para tratar el choque septico.

Legal Events

Date Code Title Description
FG Grant, registration